Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferreri, A.
Right arrow Articles by Doglioni, C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferreri, A.
Right arrow Articles by Doglioni, C
Haematologica, Vol 90, Issue 11, 1578-1579
Copyright © 2005 by Ferrata Storti Foundation

Comparative Study

Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa

AJ Ferreri, M Ponzoni, G Martinelli, G Muti, M Guidoboni, R Dolcetti, and C Doglioni

Eight patients with ocular adnexal mucosal-associated lymphpid tissue (MALT) lymphoma were treated with rituximab, at diagnosis (n=5) or relapse (n=3). All untreated patients achieved lymphoma regression, while relapsing patients had no benefit. Four responding patients experienced early relapse. The median time to progression was 5 months. The efficacy of rituximab in ocular adnexal lymphoma is lower than that reported for gastric MALT lymphomas.


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al.
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy
Ann. Onc., May 1, 2008; 19(5): 835 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, et al.
Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma
Ann. Onc., February 1, 2008; 19(2): 242 - 246.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
C. Heinz, H. Merz, M. Nieschalk, H. Mueller-Miny, P. Koch, and A. Heiligenhaus
Rituximab for the treatment of extranodal marginal zone B-cell lymphoma of the lacrimal gland
Br. J. Ophthalmol., November 1, 2007; 91(11): 1563 - 1564.
[Full Text] [PDF]

Home page
 BloodHome page
D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic
Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options
Blood, September 1, 2006; 108(5): 1451 - 1460.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.